• José Javier Gómez Marco, Susana Martín Martín, Pablo Aldaz Herce, Ana Pilar Javierre Miranda, and Coro Sánchez Hernández.
• Grupo de prevención de enfermedades infecciosas del PAPPS; CSU Las Calesas, SERMAS, Madrid, España.
• Aten Primaria. 2023 Oct 1; 55 (10): 102710102710.

ObjectiveTo review the latest published evidence on the vaccine used in our country against the herpes zoster virus, breaking down the results according to the efficacy, efficiency, effectiveness and safety of the vaccine. Include the current recommendations for vaccination.DesignSecondary review. Descriptive qualitative review. Review using the search term "herpes zoster vaccine" and "Adjuvanted recombinant Herpes Zoster subunit vaccine". Retrospective observational study.Data SourcesEmbase, Medline and Google Scholar. Selection of studies Search criterion with the terms "Shingrix vaccine" and "Adjuvanted Herpes Zoster Subunit Vaccine". Search period 2013-2023. Studies classified as clinical trials or randomized clinical trials were selected. 21 published studies were evaluated. There were no exclusions.ResultsThe evaluated studies were found to be coherent and in all of them efficacy in adult individuals in preventing viral reactivation and in preventing complications was higher than 80%. The effectiveness of the vaccine after two doses was also higher than 80%. Cost-effectiveness studies were always favourable in adults, immunodepressed patients and individuals with chronic pathology. The safety of the vaccine was evaluated in the pivotal studies and in the post-commercialization studies that were undertaken (although there were few of the latter due to the short period of time studied). The safety profile of the vaccine is very high and in the case of severe adverse effects, their frequency was similar to that of a placebo.ConclusionsWe have a safe and effective vaccine against the herpes zoster virus that allows us to protect the most vulnerable population groups against this virus.Copyright © 2023 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.

19 keywords...

hide…